Frank Gleeson

Frank Gleeson is the President and CEO of Satellos Bioscience Inc., a company that focuses on modulating cell polarity using small molecule drugs for in vivo tissue regeneration. Frank also serves as the Executive in Residence at Foundation Against Cancer Innovation Trust, providing mentoring, leadership, and fundraising support. In the past, Frank has held roles such as Chief - Commercial Operations at the Centre for Probe Development and Commercialization, President of Gleeson and Associates, and President & CEO of Destin Therapeutics Inc. Frank has a strong background in the biomedical technology industry, including leadership positions at MDS proteomics and MDS Capital Corp. Frank holds an MBA from Schulich School of Business at York University.